Warning: Potential Pancreatic Risks Linked to GLP-1 Weight Loss Injections Monday, November 24, 2025 glp1 tirzepatide semaglutide pancreatitis sideeffects weightloss nhs mhra medicationsafety yellowcard GLP-1 receptor agonists, such as tirzepatide (Mounjaro) and semaglutide (Wegovy), are popular injectable medications prescribed to support weight loss by reducing appetite and increasing feelings of fullness. Typically … Read More
Weight-loss jabs could 'significantly lower' risk of dementia Wednesday, June 25, 2025 semaglutide dementia ozempic wegovy diabetes alzheimers glp1 weightloss cardiovascular t2diabetes A groundbreaking study has found that semaglutide, the active ingredient in the diabetes drug Ozempic and the weight-loss injection Wegovy, may significantly reduce the risk of dementia in people with type 2 diabetes. … Read More
Weight-Loss Injections May Dramatically Reduce Dementia Risk Wednesday, June 25, 2025 dementia semaglutide ozempic wegovy type2diabetes alzheimers glp1r weightloss cardiovascular prevention A groundbreaking study suggests that semaglutide, the active ingredient in diabetes drug Ozempic and weight-loss injection Wegovy, could significantly decrease the risk of dementia in individuals with type 2 diabetes. … Read More
Weight-loss jab Mounjaro outperforms rival Wegovy in major study Sunday, May 11, 2025 mounjaro wegovy weightloss obesity tirzepatide semaglutide clinicaltrial glp1 gip diabetes A groundbreaking study has found that the weight-loss drug Mounjaro (tirzepatide) helps patients lose significantly more weight than its competitor, Wegovy (semaglutide). Presented at the European Congress on Obesity in … Read More